Eli Lilly Investors Await Foundayo Launch Data Amid Market Uncertainty
Eli Lilly investors are closely watching the early performance of its new weight-loss drug, Foundayo, as initial data is not yet reflected in the company's first-quarter financials. Foundayo, a competitor to Novo Nordisk's Wegovy, launched in early April, and analysts suggest it may be lagging behind. The company's stock has declined 19% this year, raising concerns about its ability to meet expectations for its obesity franchise.
Tickers: $LLY
Topics: Eli Lilly Foundayo Novo Nordisk obesity drugs pharmaceuticals stock performance